Market research firm Frost & Sullivan is presenting its 2012 Global Enabling Technology Award to Alexza Pharmaceuticals for its Staccato thermal vaporization inhaler platform. The award is designed to recognize a company for “developing a technology that enables the creation of new products and applications and/or enhances current products” along with the “potential for market acceptance and breadth of access to the technology.”
Alexza is developing several Staccato products, including an inhaled loxapine called Adasuve. The company resubmitted its NDA for Adasuve in June 2012; the PDUFA goal date is December 21, 2012. The company is also expecting an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its application for the EU in December.
According to Frost & Sullivan, “This first-in-class, anti-agitation product is expected to hold huge market potential and business opportunities in terms of commercialization.”
Frost & Sullivan Research Analyst Aiswariya Chidambaram commented, “With a single normal breath, the Staccato technology delivers an accurate, rapidly absorbed dose of loxapine through the deep lung. Loxapine, noted for its excellent receptor-binding attributes and positive side-effect profile, is likely to be a preferred antipsychotic of physicians treating agitation.”
Read the Frost & Sullivan press release.
